Polymer conjugates as anticancer nanomedicines.
The transfer of polymer-protein conjugates into routine clinical use, and the clinical development of polymer-anticancer-drug conjugates, both as single agents and as components of combination therapy, is establishing polymer therapeutics as one of the first classes of anticancer nanomedicines. There is growing optimism that ever more sophisticated polymer-based vectors will be a significant addition to the armoury currently used for cancer therapy.
Duncan
Ruth
R
Centre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3XF, UK. Duncanr@cf.ac.uk
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004337:Drug Carriers / Q000737:chemistry*; D015195:Drug Design; D057487:Enzyme Therapy; D004798:Enzymes / Q000008:administration & dosage; D006801:Humans; D008954:Models, Biological; D050997:Nanomedicine; D049329:Nanostructures / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy*; D011108:Polymers / Q000737:chemistry*; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004337:Drug Carriers; D004798:Enzymes; D011108:Polymers; D011506:Proteins